228 related articles for article (PubMed ID: 21205076)
21. Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.
Sattu K; Hochgräfe F; Wu J; Umapathy G; Schönherr C; Ruuth K; Chand D; Witek B; Fuchs J; Li PK; Hugosson F; Daly RJ; Palmer RH; Hallberg B
FEBS J; 2013 Nov; 280(21):5269-82. PubMed ID: 23889739
[TBL] [Abstract][Full Text] [Related]
22. Emerging importance of ALK in neuroblastoma.
Azarova AM; Gautam G; George RE
Semin Cancer Biol; 2011 Oct; 21(4):267-75. PubMed ID: 21945349
[TBL] [Abstract][Full Text] [Related]
23. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase.
Epstein LF; Chen H; Emkey R; Whittington DA
J Biol Chem; 2012 Oct; 287(44):37447-57. PubMed ID: 22932897
[TBL] [Abstract][Full Text] [Related]
24. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
[TBL] [Abstract][Full Text] [Related]
25. Biological role of anaplastic lymphoma kinase in neuroblastoma.
Osajima-Hakomori Y; Miyake I; Ohira M; Nakagawara A; Nakagawa A; Sakai R
Am J Pathol; 2005 Jul; 167(1):213-22. PubMed ID: 15972965
[TBL] [Abstract][Full Text] [Related]
26. Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G; Mendoza-Garcia P; Hallberg B; Palmer RH
APMIS; 2019 May; 127(5):288-302. PubMed ID: 30803032
[TBL] [Abstract][Full Text] [Related]
27. Effect of missense mutations on structure and interaction of anaplastic Lymphoma kinase (ALK) in neuroblastom.
Kanwal H; Khan MH; Rashid H
Pak J Pharm Sci; 2013 May; 26(3):611-6. PubMed ID: 23625438
[TBL] [Abstract][Full Text] [Related]
28. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain.
Lee CC; Jia Y; Li N; Sun X; Ng K; Ambing E; Gao MY; Hua S; Chen C; Kim S; Michellys PY; Lesley SA; Harris JL; Spraggon G
Biochem J; 2010 Sep; 430(3):425-37. PubMed ID: 20632993
[TBL] [Abstract][Full Text] [Related]
29. Global genomic and RNA profiles for novel risk stratification of neuroblastoma.
Ohira M; Nakagawara A
Cancer Sci; 2010 Nov; 101(11):2295-301. PubMed ID: 20731666
[TBL] [Abstract][Full Text] [Related]
30. Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma.
Cazes A; Lopez-Delisle L; Tsarovina K; Pierre-Eugène C; De Preter K; Peuchmaur M; Nicolas A; Provost C; Louis-Brennetot C; Daveau R; Kumps C; Cascone I; Schleiermacher G; Prignon A; Speleman F; Rohrer H; Delattre O; Janoueix-Lerosey I
Oncotarget; 2014 May; 5(9):2688-702. PubMed ID: 24811913
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
[TBL] [Abstract][Full Text] [Related]
32. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
[TBL] [Abstract][Full Text] [Related]
33. Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse.
Chen L; Humphreys A; Turnbull L; Bellini A; Schleiermacher G; Salwen H; Cohn SL; Bown N; Tweddle DA
Oncotarget; 2016 Dec; 7(52):87301-87311. PubMed ID: 27888620
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic anaplastic lymphoma kinase (ALK) mutation in neuroblastomas and other pediatric tumors.
Kwon MJ; Choi YL; Sung KW; Kang SY; Park SM; Choi SY; Kim JS; Suh YL
Pathol Res Pract; 2011 Oct; 207(10):634-9. PubMed ID: 21940108
[TBL] [Abstract][Full Text] [Related]
35. Targeting ALK in neuroblastoma--preclinical and clinical advancements.
Carpenter EL; Mossé YP
Nat Rev Clin Oncol; 2012 May; 9(7):391-9. PubMed ID: 22585002
[TBL] [Abstract][Full Text] [Related]
36. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
Sasaki T; Okuda K; Zheng W; Butrynski J; Capelletti M; Wang L; Gray NS; Wilner K; Christensen JG; Demetri G; Shapiro GI; Rodig SJ; Eck MJ; Jänne PA
Cancer Res; 2010 Dec; 70(24):10038-43. PubMed ID: 21030459
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells.
Schönherr C; Ruuth K; Kamaraj S; Wang CL; Yang HL; Combaret V; Djos A; Martinsson T; Christensen JG; Palmer RH; Hallberg B
Oncogene; 2012 Dec; 31(50):5193-200. PubMed ID: 22286764
[TBL] [Abstract][Full Text] [Related]
38. Potential therapies for anaplastic lymphoma kinase-driven tumors in children: progress to date.
Lowe EJ; Lim MS
Paediatr Drugs; 2013 Jun; 15(3):163-9. PubMed ID: 23696342
[TBL] [Abstract][Full Text] [Related]
39. Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy.
Ardini E; Magnaghi P; Orsini P; Galvani A; Menichincheri M
Cancer Lett; 2010 Dec; 299(2):81-94. PubMed ID: 20934803
[TBL] [Abstract][Full Text] [Related]
40. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.
Bresler SC; Weiser DA; Huwe PJ; Park JH; Krytska K; Ryles H; Laudenslager M; Rappaport EF; Wood AC; McGrady PW; Hogarty MD; London WB; Radhakrishnan R; Lemmon MA; Mossé YP
Cancer Cell; 2014 Nov; 26(5):682-94. PubMed ID: 25517749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]